Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Please indicate which comment is of concern and why. Your comments will be sent to our moderator for review.

Report comment to moderator

MandatoryRequired fields.

Headline

RPS asks Home Office for guidance on THC levels in cannabidiol oil

Comment

It doesn't appear that clear to my reading. All three elements must apply for 'exempt product' status and the CBD preparations marketed are designed for use by human beings thus the lack of recoverability or the very low content are irrelevant: “exempt product” means a preparation or other product consisting of one or more component parts, any of which contains a controlled drug, where— (a) the preparation or other product is not designed for administration of the controlled drug to a human being or animal; (b) the controlled drug in any component part is packaged in such a form, or in combination with other active or inert substances in such a manner, that it cannot be recovered by readily applicable means or in a yield which constitutes a risk to health; and (c) no one component part of the product or preparation contains more than one milligram of the controlled drug or one microgram in the case of lysergide or any other N-alkyl derivative of lysergamide;

Posted date

1 JUL 2019

Posted time

9:16

Mandatory
Mandatory
Mandatory
Mandatory

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.